Researchers are testing whether semaglutide, a weight-loss medication, can help obese patients recover better from knee replacement surgery. According to Gram Research analysis, this pilot study of 54 older Asian adults will examine whether patients can tolerate the medication for 48 weeks before and after surgery, and whether it reduces pain and complications. The medication may work through multiple pathways including weight loss, reduced inflammation, and improved metabolism—not just appetite suppression alone.
Researchers are testing whether a popular weight-loss medication called semaglutide can help obese patients recover better from knee replacement surgery. According to Gram Research analysis, this pilot study will track 54 older adults in Asia who receive either the medication or standard care before and after their surgery. The medication works by reducing appetite and may also reduce inflammation in the body. Scientists want to see if taking semaglutide for nearly a year before and after surgery improves pain relief, weight loss, and overall recovery. If successful, this could lead to larger studies proving whether the drug truly helps people have better outcomes from knee surgery.
Key Statistics
A 2026 pilot randomized controlled trial published in Bone & Joint Open will test semaglutide in 54 obese adults aged 40-80 years scheduled for knee replacement surgery in Asia, the first study of this medication as a perioperative optimization strategy in this population.
The NPO-OOPS-TKR trial will administer semaglutide for 48 weeks before and 48 weeks after total knee arthroplasty, with a four-week washout period before and after surgery, to evaluate feasibility, tolerability, and preliminary effects on pain, weight loss, and surgical complications.
Obesity increases perioperative complications and worsens pain and functional outcomes after knee replacement surgery, making preoperative optimization clinically important, though current evidence for weight-loss interventions remains mixed according to the study protocol.
The Quick Take
- What they studied: Whether a weight-loss medication called semaglutide can help obese patients recover better from knee replacement surgery by reducing pain, improving function, and preventing complications.
- Who participated: 54 adults aged 40-80 years with obesity (BMI of 27 or higher) living in Asia who are scheduled for knee replacement surgery. Half will receive semaglutide, and half will receive standard care only.
- Key finding: This is a pilot study, so it’s not yet testing whether the drug works—instead, researchers are checking if patients will take the medication as prescribed, tolerate it well, and stay in the study. These answers will determine if a larger, more definitive trial is possible.
- What it means for you: If you’re obese and facing knee replacement surgery, this research suggests a weight-loss medication might become a helpful tool to improve your recovery. However, this is early-stage research, and you should discuss any medication options with your surgeon before surgery.
The Research Details
This is a pilot randomized controlled trial, which means researchers will randomly assign 54 patients into two groups. One group receives semaglutide (a medication that reduces appetite and helps with weight loss) for 48 weeks before surgery and 48 weeks after surgery, with a four-week break before and after the operation. The other group receives standard knee surgery care and general advice about diet and exercise, but no medication.
The study is designed to answer important practical questions: Can researchers recruit enough patients? Will patients actually take the medication as prescribed? Do patients experience side effects that make them want to stop? Will patients stay in the study until the end? These “feasibility” questions are the main focus of a pilot study.
Researchers will also track exploratory outcomes like pain levels, weight changes, how well patients can walk and function, and whether complications occur during surgery and recovery. This information will help researchers design a larger, more powerful study in the future.
Obesity significantly increases the risk of complications during and after knee replacement surgery, including blood clots, infections, and poor pain control. Current approaches to weight loss before surgery have mixed results. Semaglutide is a newer medication that works differently than traditional weight-loss approaches—it reduces appetite and may also reduce inflammation throughout the body. Testing this medication in a structured trial before surgery is important because it could offer patients a new way to prepare for surgery and improve their outcomes. This pilot study is specifically designed for older Asian adults, a population that hasn’t been studied with this medication before knee surgery.
This is a well-designed pilot study because it uses randomization (randomly assigning patients to groups), which reduces bias. The study includes a clear control group for comparison. However, as a pilot study with only 54 participants, it’s not powered to prove the medication works—it’s designed to test whether a larger study is feasible. The results will be preliminary and will need confirmation in a larger trial. The study is registered and follows rigorous protocols, which increases confidence in the findings.
What the Results Show
This is a protocol paper describing a study that has not yet been completed, so there are no results to report yet. The researchers have designed the study and are preparing to recruit participants. The primary outcomes they will measure are feasibility metrics: How many eligible patients can they recruit? What percentage of patients take the medication as prescribed? How many patients experience side effects? How many patients complete the full study?
These feasibility questions are critical because if patients won’t take the medication, experience intolerable side effects, or drop out of the study, then a larger trial wouldn’t be worthwhile. The researchers are being thoughtful about testing whether this approach is practical before investing in a bigger, more expensive study.
Once the study is complete, researchers will also examine preliminary clinical outcomes like changes in pain, weight loss, patient satisfaction, and surgical complications. These preliminary results will help estimate how large a future definitive trial would need to be to prove whether semaglutide truly improves knee surgery outcomes.
The study will also explore how semaglutide affects metabolic markers (measures of how the body processes energy) and inflammatory markers (signs of inflammation in the body). This is important because semaglutide may help patients recover better through mechanisms beyond simple weight loss. The medication appears to reduce inflammation and improve metabolic health, which could independently improve surgical outcomes. The researchers will measure these biological changes to understand how the medication might be helping patients.
Previous research shows that obesity increases surgical complications and worsens pain after knee replacement. Some studies suggest that losing weight before surgery improves outcomes, but the evidence is mixed—not all weight-loss interventions work equally well. Semaglutide is a newer medication that has shown strong results for weight loss in other populations, but it has never been tested as a perioperative optimization strategy (a way to prepare patients for surgery) before knee replacement. This pilot study fills an important gap by being the first to test this approach in older Asian adults awaiting knee surgery.
This is a pilot study with only 54 participants, so results cannot prove that semaglutide works for knee surgery recovery. The study is limited to older Asian adults, so findings may not apply to other populations. The study includes a four-week washout period before and after surgery (when patients stop taking the medication), which means the medication won’t be in their system during the actual surgery—this was done for safety reasons but means the drug won’t directly affect the surgical procedure itself. The study is still in the planning phase, so no patient data has been collected yet. Future research will need to confirm any promising findings in a larger, more diverse population.
The Bottom Line
This is a pilot study, so no clinical recommendations can be made yet. However, if you are obese and scheduled for knee replacement surgery, discuss all options with your orthopedic surgeon and primary care doctor. Do not start semaglutide on your own for surgery preparation—wait for evidence from completed trials. Current standard care (physical therapy, weight management, and general health optimization) remains the evidence-based approach. Confidence level: Low, as this is preliminary research.
This research is most relevant to: (1) Obese adults aged 40-80 scheduled for knee replacement surgery, (2) Orthopedic surgeons and primary care doctors treating obese patients before surgery, (3) Researchers interested in perioperative optimization strategies, (4) Older Asian adults specifically, as this is the first study in this population. People with normal weight, those not having knee surgery, or those with contraindications to semaglutide should not apply these findings.
This is a pilot study that will take approximately 2-3 years to complete (48 weeks before surgery plus 48 weeks after surgery for each participant, plus recruitment and analysis time). Results are not expected until 2028-2029 at the earliest. If the pilot is successful, a larger definitive trial would take an additional 3-5 years. Therefore, if you need knee surgery in the near future, semaglutide-based optimization is not yet an available option—standard care remains the current approach.
Frequently Asked Questions
Can weight-loss medication help me recover better from knee replacement surgery?
Research suggests weight loss before knee surgery may improve outcomes, but semaglutide hasn’t been tested for this purpose yet. A 2026 pilot study of 54 patients will examine whether the medication is feasible and tolerable before knee surgery. Results won’t be available until 2028-2029.
Is semaglutide safe to take before and after knee surgery?
This pilot study will specifically test semaglutide’s safety and tolerability around knee surgery, including a four-week medication break before and after the operation. Current data on semaglutide safety during surgery is limited, which is why researchers are conducting this careful pilot study first.
How much weight do I need to lose before knee replacement to improve my recovery?
Research shows that losing 5-10% of body weight before surgery may improve outcomes, but individual targets vary. Discuss specific weight-loss goals with your orthopedic surgeon and primary care doctor based on your health status. Standard care includes physical therapy and lifestyle changes, not medication.
What are the side effects of semaglutide for knee surgery patients?
Common semaglutide side effects include nausea, vomiting, and constipation. This pilot study will specifically measure tolerability in knee surgery patients. The study includes a four-week washout period before surgery to minimize medication effects during the operation.
When will semaglutide be available as a treatment before knee surgery?
Semaglutide is not yet recommended for perioperative optimization before knee surgery. This pilot study will determine if a larger trial is feasible. If successful, results won’t be available until 2028-2029, with additional studies needed before clinical recommendations.
Want to Apply This Research?
- Track pre-surgery weight loss progress weekly using the app’s weight tracking feature. Set a goal to lose 5-10% of body weight before knee surgery (discuss specific targets with your doctor). Monitor adherence to any prescribed medications and physical therapy exercises.
- Users awaiting knee surgery can use the app to: (1) Log daily steps and physical activity to build strength before surgery, (2) Track meals and nutrition to support healthy weight loss, (3) Set reminders for physical therapy exercises, (4) Monitor pain levels before and after surgery to track recovery progress, (5) Log any medication side effects or concerns to discuss with their doctor.
- Create a pre-surgery optimization dashboard tracking: weekly weight, daily activity minutes, pain scores, medication adherence, and physical therapy completion. After surgery, shift to post-operative recovery tracking: pain progression, mobility improvements, swelling reduction, and return-to-activity milestones. Compare pre- and post-surgery metrics to measure overall recovery success.
This article describes a pilot research protocol that has not yet been completed. No clinical results are available yet. This information is for educational purposes only and should not be used to make medical decisions. Do not start semaglutide or any other medication for surgery preparation without explicit guidance from your orthopedic surgeon and primary care physician. Semaglutide is not currently approved or recommended for perioperative optimization before knee surgery. Always consult with your healthcare team about the safest and most effective approach for your individual situation. This research is preliminary and may not apply to all populations or surgical scenarios.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.